Steven Tobochnik1,2, Emily Lapinskas3, Jayne Vogelzang3, Keith L Ligon3,4, Jong Woo Lee5. 1. Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA. stobochnik@bwh.harvard.edu. 2. VA Boston Healthcare System, Boston, MA, USA. stobochnik@bwh.harvard.edu. 3. Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA. 4. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 5. Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
PURPOSE: The relationship between peritumoral neuronal activity, early onset clinical seizures, and glioma survival outcomes remains poorly understood. Hyperexcitability on continuous EEG in the peri-operative period was studied as a prognostic biomarker in patients with newly diagnosed IDH-wildtype diffuse glioma. METHODS: A retrospective observational cohort study was performed including adults with newly diagnosed diffuse glioma, absence of IDH1/2 mutations, and continuous EEG monitoring prior to chemoradiation and within 1 month of initial resection. EEG hyperexcitability was defined by the presence of lateralized periodic discharges and/or electrographic seizures. The primary outcome of overall survival was estimated using the Kaplan-Meier method and compared between groups using multivariate Cox proportional hazards model. RESULTS: There were 424 patients without continuous EEG and 32 with continuous EEG, of whom lateralized periodic discharges and/or electrographic seizures were seen in 17 (53%). Peri-operative EEG hyperexcitability was associated with decreased overall survival in multivariate analysis (median 12.5 [95% CI 6.2-25.6] months with hyperexcitability versus median 19.9 [95% CI 8.9-53.5] months without hyperexcitability, p = 0.043). Compared to patients without continuous EEG, overall survival was decreased in patients with hyperexcitability (p < 0.0001) and similar in patients without hyperexcitability (p = 0.193). Patients with and without hyperexcitability had similar rates of exposure to anti-seizure medication at baseline, and in long-term follow-up had no difference in number of medications required for seizure control. CONCLUSIONS: These findings indicate the potential prognostic value of a clinical EEG biomarker of glioma aggressiveness prior to the initiation of chemoradiation.
PURPOSE: The relationship between peritumoral neuronal activity, early onset clinical seizures, and glioma survival outcomes remains poorly understood. Hyperexcitability on continuous EEG in the peri-operative period was studied as a prognostic biomarker in patients with newly diagnosed IDH-wildtype diffuse glioma. METHODS: A retrospective observational cohort study was performed including adults with newly diagnosed diffuse glioma, absence of IDH1/2 mutations, and continuous EEG monitoring prior to chemoradiation and within 1 month of initial resection. EEG hyperexcitability was defined by the presence of lateralized periodic discharges and/or electrographic seizures. The primary outcome of overall survival was estimated using the Kaplan-Meier method and compared between groups using multivariate Cox proportional hazards model. RESULTS: There were 424 patients without continuous EEG and 32 with continuous EEG, of whom lateralized periodic discharges and/or electrographic seizures were seen in 17 (53%). Peri-operative EEG hyperexcitability was associated with decreased overall survival in multivariate analysis (median 12.5 [95% CI 6.2-25.6] months with hyperexcitability versus median 19.9 [95% CI 8.9-53.5] months without hyperexcitability, p = 0.043). Compared to patients without continuous EEG, overall survival was decreased in patients with hyperexcitability (p < 0.0001) and similar in patients without hyperexcitability (p = 0.193). Patients with and without hyperexcitability had similar rates of exposure to anti-seizure medication at baseline, and in long-term follow-up had no difference in number of medications required for seizure control. CONCLUSIONS: These findings indicate the potential prognostic value of a clinical EEG biomarker of glioma aggressiveness prior to the initiation of chemoradiation.
Authors: Catherine A Schevon; Steven Tobochnik; Tahra Eissa; Edward Merricks; Brian Gill; R Ryley Parrish; Lisa M Bateman; Guy M McKhann; Ronald G Emerson; Andrew J Trevelyan Journal: Neurobiol Dis Date: 2019-03-18 Impact factor: 5.996
Authors: Marco Skardelly; Elina Brendle; Susan Noell; Felix Behling; Thomas V Wuttke; Jens Schittenhelm; Sotirios Bisdas; Christoph Meisner; Sabine Rona; Marcos Soares Tatagiba; Ghazaleh Tabatabai Journal: Ann Neurol Date: 2015-10-14 Impact factor: 10.422
Authors: Megdad M Zaatreh; Dennis D Spencer; James L Thompson; Hal Blumenfeld; Edward J Novotny; Richard H Mattson; Susan S Spencer Journal: Epilepsia Date: 2002-07 Impact factor: 5.864
Authors: Varun Venkataramani; Dimitar Ivanov Tanev; Christopher Strahle; Alexander Studier-Fischer; Laura Fankhauser; Tobias Kessler; Christoph Körber; Markus Kardorff; Miriam Ratliff; Ruifan Xie; Heinz Horstmann; Mirko Messer; Sang Peter Paik; Johannes Knabbe; Felix Sahm; Felix T Kurz; Azer Aylin Acikgöz; Frank Herrmannsdörfer; Amit Agarwal; Dwight E Bergles; Anthony Chalmers; Hrvoje Miletic; Sevin Turcan; Christian Mawrin; Daniel Hänggi; Hai-Kun Liu; Wolfgang Wick; Frank Winkler; Thomas Kuner Journal: Nature Date: 2019-09-18 Impact factor: 49.962
Authors: Shota Tanaka; Tracy T Batchelor; A John Iafrate; Dora Dias-Santagata; Darrell R Borger; Leif W Ellisen; Daniel Yang; David N Louis; Daniel P Cahill; Andrew S Chi Journal: Acta Neuropathol Commun Date: 2019-04-29 Impact factor: 7.801
Authors: Humsa S Venkatesh; Wade Morishita; Anna C Geraghty; Dana Silverbush; Shawn M Gillespie; Marlene Arzt; Lydia T Tam; Cedric Espenel; Anitha Ponnuswami; Lijun Ni; Pamelyn J Woo; Kathryn R Taylor; Amit Agarwal; Aviv Regev; David Brang; Hannes Vogel; Shawn Hervey-Jumper; Dwight E Bergles; Mario L Suvà; Robert C Malenka; Michelle Monje Journal: Nature Date: 2019-09-18 Impact factor: 49.962
Authors: Mehdi Touat; Yvonne Y Li; Adam N Boynton; Liam F Spurr; J Bryan Iorgulescu; Craig L Bohrson; Isidro Cortes-Ciriano; Cristina Birzu; Jack E Geduldig; Kristine Pelton; Mary Jane Lim-Fat; Sangita Pal; Ruben Ferrer-Luna; Shakti H Ramkissoon; Frank Dubois; Charlotte Bellamy; Naomi Currimjee; Juliana Bonardi; Kenin Qian; Patricia Ho; Seth Malinowski; Leon Taquet; Robert E Jones; Aniket Shetty; Kin-Hoe Chow; Radwa Sharaf; Dean Pavlick; Lee A Albacker; Nadia Younan; Capucine Baldini; Maïté Verreault; Marine Giry; Erell Guillerm; Samy Ammari; Frédéric Beuvon; Karima Mokhtari; Agusti Alentorn; Caroline Dehais; Caroline Houillier; Florence Laigle-Donadey; Dimitri Psimaras; Eudocia Q Lee; Lakshmi Nayak; J Ricardo McFaline-Figueroa; Alexandre Carpentier; Philippe Cornu; Laurent Capelle; Bertrand Mathon; Jill S Barnholtz-Sloan; Arnab Chakravarti; Wenya Linda Bi; E Antonio Chiocca; Katie Pricola Fehnel; Sanda Alexandrescu; Susan N Chi; Daphne Haas-Kogan; Tracy T Batchelor; Garrett M Frampton; Brian M Alexander; Raymond Y Huang; Azra H Ligon; Florence Coulet; Jean-Yves Delattre; Khê Hoang-Xuan; David M Meredith; Sandro Santagata; Alex Duval; Marc Sanson; Andrew D Cherniack; Patrick Y Wen; David A Reardon; Aurélien Marabelle; Peter J Park; Ahmed Idbaih; Rameen Beroukhim; Pratiti Bandopadhayay; Franck Bielle; Keith L Ligon Journal: Nature Date: 2020-04-15 Impact factor: 49.962
Authors: Vera Belgers; Tianne Numan; Shanna D Kulik; Arjan Hillebrand; Philip C de Witt Hamer; Jeroen J G Geurts; Jaap C Reijneveld; Pieter Wesseling; Martin Klein; Jolanda Derks; Linda Douw Journal: J Neurooncol Date: 2020-01-17 Impact factor: 4.130